NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Healthcare

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.

TSXV:NGEN - Post by User

NervGen Pharma Corp

<< Previous

Bullboard Posts

Next >>

Post by deepoil0808on May 15, 2024 11:32pm

255 Views

Post# 36042573

CEO.CA post on a director

A poster brought up issues that one director is having in Court.

If true, this type of alledged conduct is very concerning, especially when person is sitting as director of NGEN.

Does not inspire confidence with investors.

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://masslawyersweekly.com/wp-content/blogs.dir/1/files/2023/12/09-142-23.pdf

Good Luck,

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project